Amgen has developed a GLP-1/GIP drug that is given monthly, while Intracia is working on an agent that is injected every six months
Arguably, the most clinically relevant basis for the potential of GLP-1 RAs in HF could be their effect on multiple cardiometabolic parameters that play intertwined roles across the HF-related diseases such as diabetes and obesity, which often co-exist
Zepbound (tirzepatide) is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist that is FDA-approved along with increased physical activity and a reduced-calorie diet for chronic weight management in adults with a starting body mass index (BMI) of: 30 kg/m^2 or higher (obesity) 27 kg/m^2 or higher (overweight) with at least one weight-related condition such as high cholesterol, high blood pressure (hypertension), type 2 diabetes, heart disease, or obstructive sleep apnea
Once youve begun taking a GLP-1, it can be easy to get wrapped up in weight lossbut Dr
Shorter subscription terms are available at higher monthly rates